Q2 EPS Estimates for UroGen Pharma Raised by HC Wainwright

UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - HC Wainwright boosted their Q2 2025 earnings per share (EPS) estimates for UroGen Pharma in a report released on Thursday, May 22nd. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.74) per share for the quarter, up from their previous forecast of ($0.75). HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for UroGen Pharma's current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for UroGen Pharma's Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.95) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.56) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.45) EPS and FY2026 earnings at ($2.14) EPS.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The company had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million.

A number of other research analysts also recently weighed in on URGN. The Goldman Sachs Group decreased their price target on UroGen Pharma from $16.00 to $3.00 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. D. Boral Capital reissued a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a report on Thursday, May 8th. LADENBURG THALM/SH SH began coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a "buy" rating and a $31.00 price target for the company. Scotiabank started coverage on UroGen Pharma in a report on Wednesday, April 16th. They issued a "sector outperform" rating and a $23.00 price objective for the company. Finally, Guggenheim decreased their price target on UroGen Pharma from $40.00 to $15.00 and set a "buy" rating on the stock in a research note on Friday, May 23rd. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $27.43.

UroGen Pharma Stock Up 3.1%

URGN stock traded up $0.12 during mid-day trading on Monday, reaching $4.05. The company had a trading volume of 1,611,325 shares, compared to its average volume of 684,362. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The stock has a 50 day simple moving average of $9.72 and a two-hundred day simple moving average of $10.55. The company has a market capitalization of $186.73 million, a price-to-earnings ratio of -1.29 and a beta of 0.66. UroGen Pharma has a 52 week low of $3.42 and a 52 week high of $20.70.

Institutional Investors Weigh In On UroGen Pharma

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in UroGen Pharma by 4.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company's stock worth $231,000 after buying an additional 969 shares during the period. Wellington Management Group LLP raised its stake in UroGen Pharma by 0.8% during the 1st quarter. Wellington Management Group LLP now owns 148,078 shares of the company's stock worth $1,638,000 after buying an additional 1,125 shares during the period. Rhumbline Advisers raised its stake in UroGen Pharma by 2.8% during the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company's stock worth $546,000 after buying an additional 1,402 shares during the period. MetLife Investment Management LLC raised its stake in UroGen Pharma by 13.6% during the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company's stock worth $242,000 after buying an additional 2,727 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in UroGen Pharma by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company's stock worth $996,000 after buying an additional 3,024 shares during the period. Institutional investors own 91.29% of the company's stock.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.